We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile.
- Authors
Vaglio, Augusto; Alberici, Federico; Maggiore, Umberto; Buti, Sebastiano; Potenzoni, Domenico; Passalacqua, Rodolfo; Buzio, Carlo
- Abstract
Objective: We report the results obtained using an original immunotherapy schedule featuring chronically administered low-dose interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with metastatic renal cell carcinoma (mRCC), and we assess treatment efficacy according to the patients’ prognostic profiles. Methods: 138 consecutive patients were enrolled, and received IL-2 (1 million IU/m2) subcutaneously twice daily on days 1 and 2, and once daily on days 3–5 of each week, and IFN-α (1.8 million IU/m2) intramuscularly once daily on days 3 and 5. Each cycle consisted of 4 consecutive weeks and was repeated indefinitely at 4-month intervals regardless of response. The patients’ baseline risk profile was assessed using Negrier’s stratification system. Results: The overall response rate was 10.9% (95% CI 6.7–17.2), and median overall survival was 19.6 months (95% CI 14.2–28.2). Treatment-related toxicity was mostly WHO grade 2 or below. Survival in the low-, intermediate- and high-risk groups was significantly different (p for trend <0.001), with low-risk patients having a median survival of 65.1 months (95% CI 42.7–84.2). Conclusion: Chronically administered low-dose IL-2 and IFN-α may be a safe and effective option for low-risk mRCC patients. Copyright © 2008 S. Karger AG, Basel
- Subjects
IMMUNOTHERAPY; CLINICAL immunology; INTERLEUKIN-2; IMMUNOMODULATORS; INTERFERONS
- Publication
Oncology, 2009, Vol 76, Issue 1, p69
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000178810